Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | BCL6 | P41182 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24033281 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHDAC1BCL6 | |
| SCHEMBL24033556 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AHDAC1BCL6 | |
| SCHEMBL24033465 | 0.90 | HDAC1 (0.45) | SMN1; SMN2NPC1RAB9AHDAC1ALDH1A1 | |
| SCHEMBL24033324 | 0.90 | HDAC1 (0.45) | SMN1; SMN2NPC1RAB9AHDAC1ALDH1A1 | |
| SCHEMBL24033321 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL24815989 | 0.90 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL24033280 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL25491097 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL25189951 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1GAA | |
| SCHEMBL25491094 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | CHDI FOUNDATION, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2021231571-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | CHDI FOUNDATION, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409615-A1 | HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | SMN1; SMN2 348/4885NPC1 777/4885RAB9A 1713/4885 |
| US-11806346-B2 | HTT modulators for treating Huntington's disease | HTT, HYPK, ATXN2 | SMN1; SMN2 348/4885NPC1 777/4885RAB9A 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.